Friedreich Ataxia - Pipeline Review, H2 2011

Document Sample
Friedreich Ataxia - Pipeline Review, H2 2011 Powered By Docstoc
					Friedreich Ataxia – Pipeline Review, H2 2011




                 Friedreich Ataxia - Pipeline Review, H2 2011
                                                                                          Reference Code: GMDHC1416IDB

                                                                                          Publication Date: October 2011




Friedreich Ataxia – Pipeline Review, H2 2011                                                                     GMDHC1416IDB / Pub October 2011
© Global Markets Direct. This report is a licensed product and is not to be photocopied                                                  Page(1)
Friedreich Ataxia – Pipeline Review, H2 2011



Ta b le o f Co n te n ts
Table of Contents ..................................................................................................................................................................................................... 2
      List of Tables...................................................................................................................................................................................................... 4
      List of Figures .................................................................................................................................................................................................... 5
Introduction .............................................................................................................................................................................................................. 6
      Global Markets Direct Report Coverage ............................................................................................................................................................. 6
Friedreich Ataxia Overview ....................................................................................................................................................................................... 7
Therapeutics Development ....................................................................................................................................................................................... 8
      An Overview of Pipeline Products for Friedreich Ataxia ...................................................................................................................................... 8
Friedreich Ataxia Therapeutics under Development by Companies .........................................................................................................................10
Friedreich Ataxia Therapeutics under Investigation by Universities/Institutes ...........................................................................................................11
Late Stage Products ................................................................................................................................................................................................12
      Comparative Analysis .......................................................................................................................................................................................12
Mid Clinical Stage Products .....................................................................................................................................................................................13
      Comparative Analysis .......................................................................................................................................................................................13
Early Clinical Stage Products ..................................................................................................................................................................................14
      Comparative Analysis .......................................................................................................................................................................................14
Pre-Clinical Stage Products .....................................................................................................................................................................................15
      Comparative Analysis .......................................................................................................................................................................................15
Friedreich Ataxia Therapeutics - Products under Development by Companies ........................................................................................................16
Friedreich Ataxia Therapeutics - Products under Investigation by Universities/Institutes ..........................................................................................17
Companies Involved in Friedreich Ataxia Therapeutics Development ......................................................................................................................18
      Apotex, Inc. .......................................................................................................................................................................................................18
      Ipsen S.A. .........................................................................................................................................................................................................18
      Repligen Corporation ........................................................................................................................................................................................19
      Santhera Pharmaceuticals Holding AG .............................................................................................................................................................19
      Endo Pharmaceuticals Inc. ................................................................................................................................................................................20
      Edison Pharmaceuticals, Inc. ............................................................................................................................................................................20
      Varinel, Inc. .......................................................................................................................................................................................................21
Friedreich Ataxia - Therapeutics Assessment ..........................................................................................................................................................22
      Assessment by Monotherapy Products .............................................................................................................................................................22
      Assessment by Route of Administration ............................................................................................................................................................23
      Assessment by Molecule Type ..........................................................................................................................................................................25
Drug Profiles ...........................................................................................................................................................................................................27
      A0001 - Drug Profile..........................................................................................................................................................................................27
            Product Description ....................................................................................................................................................................................27
            Mechanism of Action...................................................................................................................................................................................27
            R&D Progress .............................................................................................................................................................................................27
      VAR10300 - Drug Profile ...................................................................................................................................................................................29
            Product Description ....................................................................................................................................................................................29
            Mechanism of Action...................................................................................................................................................................................29
            R&D Progress .............................................................................................................................................................................................29
      VAR-10100 - Drug Profile..................................................................................................................................................................................30
            Product Description ....................................................................................................................................................................................30
            Mechanism of Action...................................................................................................................................................................................30
            R&D Progress .............................................................................................................................................................................................30
      Epoetin Alfa - Drug Profile .................................................................................................................................................................................31
            Product Description ....................................................................................................................................................................................31


Friedreich Ataxia – Pipeline Review, H2 2011                                                                                                                  GMDHC1416IDB / Pub October 2011
© Global Markets Direct. This report is a licensed product and is not to be photocopied                                                                                                                                Page(2)
Friedreich Ataxia – Pipeline Review, H2 2011


           Mechanism of Action...................................................................................................................................................................................31
           R&D Progress .............................................................................................................................................................................................31
     Catena - Drug Profile ........................................................................................................................................................................................32
           Product Description ....................................................................................................................................................................................32
           Mechanism of Action...................................................................................................................................................................................32
           R&D Progress .............................................................................................................................................................................................32
     RG2833 - Drug Profile.......................................................................................................................................................................................34
           Product Description ....................................................................................................................................................................................34
           Mechanism of Action...................................................................................................................................................................................34
           R&D Progress .............................................................................................................................................................................................34
     Idebenone - Drug Profile ...................................................................................................................................................................................35
           Product Description ....................................................................................................................................................................................35
           Mechanism of Action...................................................................................................................................................................................35
           R&D Progress .............................................................................................................................................................................................35
     EGb 761 - Drug Profile ......................................................................................................................................................................................36
           Product Description ....................................................................................................................................................................................36
           Mechanism of Action...................................................................................................................................................................................36
           R&D Progress .............................................................................................................................................................................................36
     Pioglitazone - Drug Profile.................................................................................................................................................................................37
           Product Description ....................................................................................................................................................................................37
           Mechanism of Action....................................................................................
				
DOCUMENT INFO
Description: Friedreich Ataxia - Pipeline Review, H2 2011 Summary Global Markets Direct’s, 'Friedreich Ataxia - Pipeline Review, H2 2011', provides an overview of the Friedreich Ataxia therapeutic pipeline. This report provides information on the therapeutic development for Friedreich Ataxia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Friedreich Ataxia. 'Friedreich Ataxia - Pipeline Review, H2 2011' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - A snapshot of the global therapeutic scenario for Friedreich Ataxia. - A review of the Friedreich Ataxia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Friedreich Ataxia pipeline on the basis of route of administration and molecule type. - Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Friedreich Ataxia. - Identify emerging players with potentially strong product portfolio and design effectiv
BUY THIS DOCUMENT NOW PRICE: $500 100% MONEY BACK GUARANTEED
PARTNER GlobalMarketsDirect
Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality company and market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information. Global Markets Direct has a broad range of coverage over key market segments. It has a global scope, covering a broad range of countries constituting more than 90% of global revenues in each of the industries it covers. With a large dedicated research and analysis capability, Global Markets Direct employs rigorous primary and secondary research techniques in developing unique data sets and research materials. Its status as an independent research company allows Analysts to conduct trade interviews with key industry players. Access to unique databases of in-house market information further strengthens research and analysis capabilities. Materials are reviewed shaped by an expert panel of leading industry figures and representatives from key players in the relevant industries